These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A novel homozygous variant in PMVK is associated with enhanced IL1β secretion and a hyper-IgD syndrome-like phenotype. Jairaman A; Badiger VA; Raj S; Nair KV; Balan S; Narayanan DL Clin Genet; 2024 Mar; 105(3):302-307. PubMed ID: 38018277 [TBL] [Abstract][Full Text] [Related]
3. A possibly new autoinflammatory disease due to compound heterozygous phosphomevalonate kinase gene mutation. Yıldız Ç; Gezgin Yıldırım D; Inci A; Tümer L; Cengiz Ergin FB; Sunar Yayla ENS; Esmeray Şenol P; Karaçayır N; Eğritaş Gürkan Ö; Okur I; Ezgü FS; Bakkaloğlu SA Joint Bone Spine; 2023 Jan; 90(1):105490. PubMed ID: 36410683 [TBL] [Abstract][Full Text] [Related]
4. A Novel PMVK Variant Associated with Familial Porokeratosis. Zhang W; Nie X; Shi L; Shao F; Cao L Hum Hered; 2023; 88(1):50-57. PubMed ID: 37315547 [TBL] [Abstract][Full Text] [Related]
5. Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. Munoz MA; Jurczyluk J; Simon A; Hissaria P; Arts RJW; Coman D; Boros C; Mehr S; Rogers MJ Front Immunol; 2019; 10():1900. PubMed ID: 31474985 [TBL] [Abstract][Full Text] [Related]
6. Spectrum of clinical features and genetic variants in mevalonate kinase (MVK) gene of South Indian families suffering from Hyperimmunoglobulin D Syndrome. Govindaraj GM; Jain A; Peethambaran G; Bhoyar RC; Vellarikkal SK; Ganapati A; Sandhya P; Edavazhippurath A; Dhanasooraj D; Puthenpurayil JM; Chakkiyar K; Mishra A; Batra A; Punnen A; Kumar S; Sivasubbu S; Scaria V PLoS One; 2020; 15(8):e0237999. PubMed ID: 32822427 [TBL] [Abstract][Full Text] [Related]
7. Loss-of-function Mutation in PMVK Causes Autosomal Dominant Disseminated Superficial Porokeratosis. Wang J; Liu Y; Liu F; Huang C; Han S; Lv Y; Liu CJ; Zhang S; Qin Y; Ling L; Gao M; Yu S; Li C; Huang M; Liao S; Hu X; Lu Z; Liu X; Jiang T; Tang Z; Zhang H; Guo AY; Liu M Sci Rep; 2016 Apr; 6():24226. PubMed ID: 27052676 [TBL] [Abstract][Full Text] [Related]
8. Compromised Protein Prenylation as Pathogenic Mechanism in Mevalonate Kinase Deficiency. Politiek FA; Waterham HR Front Immunol; 2021; 12():724991. PubMed ID: 34539662 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-874 targets phosphomevalonate kinase and inhibits cancer cell growth via the mevalonate pathway. Aersilan A; Hashimoto N; Yamagata K; Yokoyama M; Nakayama A; Shi X; Nagano H; Sakuma I; Nohata N; Kinoshita T; Seki N; Rahmutulla B; Kaneda A; Zhahara SN; Gong Y; Nishimura M; Kawauchi S; Kawakami E; Tanaka T Sci Rep; 2022 Nov; 12(1):18443. PubMed ID: 36323841 [TBL] [Abstract][Full Text] [Related]
10. Phosphomevalonate Kinase Controls β-Catenin Signaling via the Metabolite 5-Diphosphomevalonate. Chen Z; Zhou X; Zhou X; Tang Y; Lu M; Zhao J; Tian C; Wu M; Liu Y; Prochownik EV; Wang F; Li Y Adv Sci (Weinh); 2023 Apr; 10(12):e2204909. PubMed ID: 36808719 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. Karacan İ; Balamir A; Uğurlu S; Aydın AK; Everest E; Zor S; Önen MÖ; Daşdemir S; Özkaya O; Sözeri B; Tufan A; Yıldırım DG; Yüksel S; Ayaz NA; Ömeroğlu RE; Öztürk K; Çakan M; Söylemezoğlu O; Şahin S; Barut K; Adroviç A; Seyahi E; Özdoğan H; Kasapçopur Ö; Turanlı ET Rheumatol Int; 2019 May; 39(5):911-919. PubMed ID: 30783801 [TBL] [Abstract][Full Text] [Related]
12. Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra. Peciuliene S; Burnyte B; Gudaitiene R; Rusoniene S; Drazdiene N; Liubsys A; Utkus A Pediatr Rheumatol Online J; 2016 Mar; 14(1):19. PubMed ID: 27012807 [TBL] [Abstract][Full Text] [Related]
13. Two Novel and Three Recurrent Mutations in the Mevalonate Pathway Genes in Chinese Patients with Porokeratosis. Wang X; Ouyang X; Zhang D; Zhu Y; Wu L; Xiao Z; Yu S; Li W; Li C Clin Cosmet Investig Dermatol; 2024; 17():191-197. PubMed ID: 38283795 [TBL] [Abstract][Full Text] [Related]
14. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. van der Burgh R; Ter Haar NM; Boes ML; Frenkel J Clin Immunol; 2013 Jun; 147(3):197-206. PubMed ID: 23110805 [TBL] [Abstract][Full Text] [Related]
15. Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency. Schneiders MS; Houten SM; Turkenburg M; Wanders RJ; Waterham HR Arthritis Rheum; 2006 Jul; 54(7):2306-13. PubMed ID: 16802371 [TBL] [Abstract][Full Text] [Related]
16. Twists and turns of the genetic story of mevalonate kinase-associated diseases: A review. Touitou I Genes Dis; 2022 Jul; 9(4):1000-1007. PubMed ID: 35685471 [TBL] [Abstract][Full Text] [Related]
17. Targeting phosphomevalonate kinase enhances radiosensitivity via ubiquitination of the replication protein A1 in lung cancer cells. Park SS; Kwon MR; Ju EJ; Shin SH; Park J; Ko EJ; Son GW; Lee HW; Kim YJ; Moon GJ; Park YY; Song SY; Jeong SY; Choi EK Cancer Sci; 2023 Sep; 114(9):3583-3594. PubMed ID: 37650703 [TBL] [Abstract][Full Text] [Related]